Skip to main content
Research Use Only 57-Product Catalog Flexible Order Quantities Batch-Document Support U.S. Fulfilment for Selected Stock Tracked Shipping Options Custom Synthesis & OEM Research Use Only 57-Product Catalog Flexible Order Quantities Batch-Document Support U.S. Fulfilment for Selected Stock Tracked Shipping Options Custom Synthesis & OEM

Material & batch records

Reta

Compare the material specification with the scope of the available records.

Reta — existing catalog illustration
Existing catalog illustration. A pictured label is not a batch result and may differ from the selected specification.

Modified peptide / Material & batch records

Modified peptide
Specification & documents

Reta is used here as a catalog shorthand for retatrutide, a peptide investigated at GIP, GLP-1 and glucagon receptors.

MATERIALReta
SPECIFICATION8 catalog options
DOCUMENT SCOPEConfirm the offered lot
USELaboratory research only
Catalog specification — select for your inquiry

Selected: 5 mg × 10 vials

Nominal catalog options, not a live availability guarantee. Final supply is confirmed in the written quotation.

Evidence for the offered material

Batch records

No matching public batch attachment was found on this product page during this catalog review. Request the documents for the offered lot; this does not mean no testing exists.

Identity

Keep the catalog reference, full material name, modification specification and requested amount together. Confirm any proposed substitution rather than relying on an abbreviation.

Analytical scope

Ask which tests and underlying files are available, what each result measures and which batch it covers. Do not infer a test result from an image or badge.

Order match

Match product name, selected specification, lot reference and packaging to the quotation. Ask about any difference before confirming supply.

Material profile

Material identity

Reta is used here as a catalog shorthand for retatrutide, a peptide investigated at GIP, GLP-1 and glucagon receptors.

For Reta, a document is useful only when its sample description matches the requested material. This page keeps reference identity, catalog quantities and batch-document scope separate.

The key distinction
Keep the catalog reference, full material name, modification specification and requested amount together. Confirm any proposed substitution rather than relying on an abbreviation.

Catalog & quotation

Catalog specification

Catalog materialReta
Material classModified peptide
Listed options5 mg × 10 vials
10 mg × 10 vials
15 mg × 10 vials
20 mg × 10 vials
30 mg × 10 vials
40 mg × 10 vials
50 mg × 10 vials
60 mg × 10 vials
Identity / supplied formKeep the catalog reference, full material name, modification specification and requested amount together. Confirm any proposed substitution rather than relying on an abbreviation.
Identity, purity and contentRequest the method, acceptance specification and lot-specific results. Chromatographic purity and net material content are separate measurements.
Storage / stabilityFollow the written instructions for the actual material and batch. No universal 24-month shelf life or solution stability is assumed.
Catalog options are inquiry specifications, not a live stock feed. The final quotation must confirm the material, amount, packaging and document scope.

Scientific context

Research background

The three-receptor research context distinguishes retatrutide from single- or dual-receptor molecules. Published studies do not certify a supplier's batch or establish a research vial as a trial formulation.

01

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

The New England journal of medicine · 2023 · PMID 37366315

Read the named material, experimental model, controls and limitations in the original paper. This source is scientific background, not a certificate for the offered lot.

Read the primary publication ↗
02

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

Lancet (London, England) · 2023 · PMID 37385280

Read the named material, experimental model, controls and limitations in the original paper. This source is scientific background, not a certificate for the offered lot.

Read the primary publication ↗

For laboratory research use only. Not for human or veterinary use, diagnosis or therapeutic application. No administration or dosing protocol is provided.

Before you inquire

Document questions

Can Reta and Retatrutide orders be combined automatically?

Keep the catalog reference, full material name, modification specification and requested amount together. Confirm any proposed substitution rather than relying on an abbreviation.

What should my Reta inquiry include?

Include the exact material name, the catalog option or required specification, quantity, destination and any documents needed before quotation. Keep nominal amount per container separate from the number of containers.

Does the catalog image confirm the selected specification?

No. It is a catalog illustration. The image may show one variant while the selector lists other options. Use the written quotation and matching batch documents to confirm supply.

Does a paper or an existing report validate every future batch?

No. A paper describes its studied material and model. An analytical report describes a named sample. Confirm the connection between any report and the lot offered for your order.

Catalog content reviewed 26 September 2026. Listed options are from this site's product records. Scientific sources, where shown, describe research context, not batch certification.

Connect the material to the document.

Include the material, amount and evidence your laboratory needs to review.

Prepare an inquiry